Severe Sepsis Due To Community-acquired Pneumonia (CAP) In Population Under Age 65

2010

Validation Of Ecurb In Community-Acquired Pneumonia: Which Gold Standard Are We Talking About?

2011

Accuracy Of Non-Invasive Methods For The Evaluation Of Oxygenation Status In Community-Acquired Pneumonia: Comparison Of PaO2/FiO2 Calculated From Se…

2012

Is Cap Etioloy Inluenced By Climate And Seasonality?

2011

Less Is More: Different Weight of the ATS/IDSA'07 Minor Criteria on Mortality Prediction in Severe Pneumonia (SCAP).

2009

Non-neuronal cholinergic system contributes to corticosteroid resistance in chronic obstructive pulmonary disease patients

2016

Background: Inhaled corticosteroid (ICS) with long-acting beta-2 agonists is a well-documented combination therapy for chronic obstructive pulmonary disease (COPD) based on its additive anti-inflammatory properties. By contrast, the recommendation of ICS in combination with long-acting muscarinic antagonist (LAMA) is not evidence-based. In this study, neutrophils obtained from COPD patients were used to compare the anti-inflammatory effects of aclidinium bromide (a long-acting muscarinic antagonist) with corticosteroids and their potential additive effect. Methods: Human sputum and blood neutrophils were isolated from healthy individuals ( n = 37), patients with stable COPD ( n = 52) and th…

Outpatient Treatment And Community Acquired Pneumonia (CAP): A Comparative Study With Hospital Admission

2011

Differences between Community Acquired Legionnaire's Pneumonia (CAP-L) and Pneumococcal Pneumonia (CAP-P).

2009

Should Broad-Spectrum Antibiotic Be Recommended For Pneumococcal Health-Care Associated Pneumonia?

2011

Community Acquired Pneumonia (CAP) With PSI V Admitted To Intensive Care Unit (ICU). Comparative Study

2010

Phenotypic Characteristics And Outcomes Of Early Pneumonia Diagnosis (within 24 Hours)

2011

Long-term Prognostic Value Of CURB-65 In Community-acquired Pneumonia

2010

Differential Features Of Community Acquired Pneumonia (CAP) In Young Adults

2011

Hypoxemia Adds to the CURB-65 Pneumonia Severity Score in Hospitalized Patients With Mild Pneumonia

2011

BACKGROUND: Hypoxemia may influence the prognosis of patients with mild pneumonia, regardless of the initial CURB-65 score (confusion, blood urea nitrogen > 20 mg/dL, respiratory rate > 30 breaths/min, blood pressure < 90/60 mm Hg, and age ≥ 65 y). OBJECTIVE: To determine the risk factors associated with hypoxemia and the influence of hypoxemia on clinical outcomes in hospitalized patients with mild pneumonia. METHODS: We performed a multicenter prospective cohort study of 585 consecutive hospitalized patients with mild pneumonia (CURB-65 groups 0 and 1). We stratified the patients according to the presence of hypoxemia, defined as a PaO2/FIO2 < 300 mm Hg on admission. We assessed the risk …

Antibiotic Use Prior To Admission And Community Acquired Pneumonia (CAP)

2011

WHY LOW RISK COMMUNITTY ACQUIRED PNEUMONIA (PSI I-III) ARE ADMITTED TO ICU?

2010

CHARACTERISTICS OF COMMUNITTY ACQUIRED PNEUMONIA IN VERY ELDERLY PATIENTS

2010

Additional file 1: of Non-neuronal cholinergic system contributes to corticosteroid resistance in chronic obstructive pulmonary disease patients

2016

Supplementary Table S1. Maximal percentage of inhibition of IL-8, MMP-9, CCL-5, GM-CSF and IL-1β release from neutrophils of healthy subjects and COPD patients. Neutrophils were incubated with aclidinium (Acl; 0.1nM-1 μM), fluticasone (Flut; 0.1nM-1 μM), formoterol (Form; 0.01nM-100nM) or salmeterol (Salm; 0.1nM-1 μM) in response to LPS (1 μg/ml) or cigarette smoke extract (CSE 5 %). The levels of different cytokines in the cell supernatant were determined and the maximal percent of inhibitions were calculated. Values are mean ± SD of 3 independent experiments run in triplicate. *p 

Additional file 2: of Non-neuronal cholinergic system contributes to corticosteroid resistance in chronic obstructive pulmonary disease patients

2016

Supplementary Figure E1. Effects of formoterol and salmeterol on pro-inflammatory markers. Concentration-dependent inhibition of lipopolysaccharide (LPS)-induced cytokines or MMP-9 release by formoterol (Form) and salmeterol (Salm) from peripheral blood neutrophils of healthy subjects and COPD patients. Neutrophils were preincubated with Salm (0.1nM-1 μM) or form (0.01nM-100nM) for 1 h followed by cell stimulation with LPS (1 μg/ml) for 6 h. Results are expressed as means ± SD of n = 3 (3 cell healthy and 3 cell COPD populations run in triplicate) independent experiments. Two-way ANOVA was followed by the post hoc Bonferroni test. *p